Diagnostic value of microRNA-143 in predicting in-stent restenosis for patients with lower extremity arterial occlusive disease by unknown
Yu et al. Eur J Med Res  (2017) 22:2 
DOI 10.1186/s40001-016-0240-y
RESEARCH
Diagnostic value of microRNA-143 
in predicting in-stent restenosis for patients 
with lower extremity arterial occlusive disease
Zhi‑Hai Yu*, Hai‑Tao Wang and Can Tu
Abstract 
Purpose: This study was conducted to explore the diagnostic value of microRNA‑143 (miRNA‑143) in predicting in‑
stent restenosis (ISR) of lower extremity arterial occlusive disease (LEAOD).
Methods: From February 2012 to March 2015, 165 patients (112 males and 53 females) with LEAOD undergoing 
interventional treatment were enrolled in this study. Serum miRNA‑143 expression was detected using quantitative 
real‑time polymerase chain reaction (qRT‑PCR). Patients were assigned into the restenosis and non‑restenosis groups 
according to routine surveillance postoperative angiography. A logistic regression analysis was conducted to analyze 
the risk factors for ISR in LEAOD patients. A receiver operating characteristic (ROC) curve was drawn to evaluate the 
diagnostic value of miRNA‑143 in predicting ISR for LEAOD patients.
Results: There were 74 and 91 patients in the restenosis and non‑restenosis groups, respectively. Before the treat‑
ment, there were significant differences in history of diabetes, smoking status, blood sugar level (BSL) at admission, 
low‑density lipoprotein cholesterol (LDL‑C) level, and stent diameter between the restenosis and non‑restenosis 
groups (all P < 0.05). Serum miRNA‑143 expression was lower in the restenosis group than in the non‑restenosis group 
(P < 0.05). Serum miRNA‑143 expression in the restenosis group was correlated with smoking status, history of diabe‑
tes, BSL, and LDL‑C (all P < 0.05). Logistic regression analysis demonstrated that miRNA‑143, LDL‑C, and smoking status 
were correlated with the postoperative ISR (all P < 0.05). ROC curve analysis revealed that the area under the curve 
(AUC) of miRNA‑143 in predicting ISR for LEAOD patients was 0.866.
Conclusion: Our results indicate that miRNA‑143 can be a promising tool for predicting the ISR in LEAOD patients.
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Background
Lower extremity arterial occlusive disease (LEAOD), 
derived from atherosclerosis, is a vascular disease with a 
high incidence of coronary artery disease and even limb 
loss worldwide [1]. Currently, endovascular interven-
tional treatment, with advanced techniques and devices, 
has been widely used in the treatment of artery occlu-
sive disease [2, 3]. Despite endovascular interventional 
treatment’s high success rate and repeatability, one of its 
implications is in-stent restenosis (ISR), which results 
from a reduced vessel patency in the wake of vascular 
endothelial injury and intimal hyperplasia followed by 
thrombosis. ISR can influence the prognosis of patients 
[4, 5]. A previous study has suggested that intimal hyper-
plasia is implicated in the pathogenesis of restenosis, 
which constitutes the major cause of treatment failure 
[6]. Luminal narrowing and intimal hyperplasia are cor-
related with the proliferation of vascular smooth muscle 
cells (VSMCs), which make it possible to prevent ISR by 
inhibiting the highly proliferating VSMCs [7]. Therefore, 
it is important to explore how molecular biology and 
genetics affect the migration and proliferation of VSMCs, 
which may lead to an effective method for the prediction 
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MicroRNAs (miRNAs) are a novel class of endoge-
nous, non-protein coding, small RNA molecules that can 
modulate hundreds of genes [8]. Their altered levels have 
been reported in patients with various diseases, such as 
heart failure and coronary artery disease [9]. Found in a 
wide range of human diseases, miRNAs have been iden-
tified as a novel biomarker for various physiological and 
pathological conditions [10]. It has been discovered that 
miRNA-143, lying on human chromosome 5 (1.7 kb), and 
highly expressive in VSMCs, plays a crucial part in the 
migration and proliferation of VSMCs [11]. Importantly, 
the expression of miRNA-143 has been reported to vary 
with the oscillation of VSMCs between differentiated and 
proliferative phenotypes [12]. Although several previous 
studies have been conducted to probe the expression of 
miRNAs in LEAOD [1, 13], few have reported details of 
the correlation between miRNA-143 and ISR in LEAOD. 
This study was conducted to provide a better solution to 
intervening in LEAOD with further insight into the mol-
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Subjects
From February 2012 to March 2015, a total of 165 patients 
(112 males and 53 females, mean age: 65.0 ±  8.3  years) 
aged from 45 to 78  years old with LEAOD who under-
went treatment in the Department of Vascular Surgery of 
the Affiliated Hospital of School of Medicine of Ningbo 
University were enrolled in this study. All subjects were 
diagnosed with LEAOD at different levels after under-
going computed tomography angiography (CTA). The 
inclusion criteria were as follows: weakened or lack of 
arterial pulse, nutritional disorders, and paleness in the 
lower extremities. Risk factors such as hyperglycemia, 
hyperlipidemia, hypertension, age, and smoking status 
were taken into consideration. Exclusion criteria were as 
follows: (1) patients with an implanted stent who refused 
to undergo a CTA review; (2) patients who did not take 
anti-platelet aggregation drugs; (3) patients who had ISR 
in two or more locations and received revascularization 
therapy within 1  month after the diagnosis of ISR; (4) 
patients with severe left ventricular dysfunction whose 
ejection fraction was below 40%; (5) patients with com-
bined incomplete function of important organs, such as 
liver dysfunction (various pathogenic factors cause seri-
ous damage to the liver parenchymal cells and Kupffer 
cells), kidney dysfunction (serious glomerular damage, 
body disorders in the excretion of metabolic waste and 
water electrolyte and acid–base regulation balance), lung 
dysfunction (respiratory failure), brain dysfunction (brain 
injury and concussion), infection (bacteria, viruses, and 
parasites), poisoning (organic phosphorus poisoning and 
poisonous gas), cardiac and cerebral vascular diseases 
(cerebral hemorrhage, cerebral thrombosis and hyperten-
sion), brain aging, brain tumors, and other dysfunction of 
water, electrolyte, and pH balance, osmotic pressure, and 
other internal environmental factors; (6) patients who 
had connective tissue diseases, autoimmune diseases, or 
malignancy; and (7) patients who had a history of acute 
myocardial infarction.
Interventional treatment
An appropriate interventional treatment was chosen 
based on preoperative CTA imaging. The ipsilateral 
femoral artery was the top priority if stenosis or occlu-
sion occurred in the middle or distal third segment of the 
superficial femoral artery or in the popliteal artery. When 
stenosis or occlusion occurred in the common femoral 
artery, proximal third segment of the superficial femoral 
artery, or the iliac artery, the patient required an intracav-
itary therapy (including catheter directed thrombolysis 
(CDT), pharmaco mechanical CDT (PCDT), percuta-
neous aspiration (PAT), protective inserting Greenfield 
caval filter, and balloon dilation combined with stent 
implantation) [14]. A retrograde puncture of the lateral 
femoral artery to conduct the intracavitary therapy was 
made with “crosses sheath.” If the bilateral femoral arter-
ies were not in proper condition to be punctured in this 
way, the puncture was made through the brachial artery. 
After the end of the puncture, patients who underwent 
local anesthesia were implanted with a sheathing canal, 
through which angiography of the targeted arteries was 
carried out to select the therapeutic regimen. Percuta-
neous transluminal angioplasty (PTA) was employed for 
patients whose vascular stenosis was shorter than 3  cm 
while an endovascular stent (ES) was used for patients 
whose residual stenosis accounted for more than 30% 
after PTA. For the patients with arterial stenosis longer 
than 10  cm or with total occlusion, rotational atherec-
tomy was applied. Under those conditions, differ-
ent types of guidewire were chosen based on different 
approaches and forming methods. The ev3 NanoCross 
and Bantam were selected for PTA microballoon, and the 
self-expandable metallic stents (ev3 ProtegeEverFlex and 
BARD LifeStent XL) were adopted as the stent.
Sample collection
A total of 10 mL of venous blood was obtained from all 
patients (anticoagulant tubes containing sodium citrate). 
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Plasma was obtained within 4  h before it was centri-
fuged in accordance with the standard Ficoll density 
gradient centrifugation. Centrifugal conditions were as 
follows: 1800g at room temperature for 10  min and let 
sit at room temperature. Plasma was bottled into 1-mL 
nuclease Eppendorf (EP) tubes and refrigerated in an 
ultra-low-temperature refrigerator at −80 °C. Five μL of 
the RNA sample was taken out for RNA extraction using 
the miRNeasy Mini Kit (Applied Biosystems Company, 
CA, USA) in accordance with the instructions. Accord-
ing to the instructions of the Tiangen miRcute miRNA 
cDNA first strand synthesis reagents kit (Fermentas, 
Thermo Fisher Scientific, Waltham, Massachusetts, 
USA), miRNA was first modified by adding Poly (A) to 
the end of the miRNA3 and then centrifuged for a short 
time before its reaction, followed by a brief centrifugation 
of reverse transcription with the universal Oligo (DT)-
Universal Tag primer. Next, it reacted for 60 min at 37 °C, 
followed by the generation of the first strand of cDNA, 
the counterpart of miRNA, which was then placed under 
−20 °C and let sit.
Quantitative real‑time polymerase chain reaction 
(qRT‑PCR)
Serum miRNA-143 expression was measured in the 
plasma of each patient using qRT-PCR. U6 was employed 
as an internal control. Primers were synthesized by the 
Shanghai Invitrogen company (Shanghai, China). Primer 
sequences are presented in Table  1. The testing process 
was carried out in accordance with the instructions of 
Taqman miRNA assays, and the reaction was conducted 
with the Prism Sequence Detection System ABI HT 7900 
PCR instrument. The conditions for PCR circulation 
involved the following: 40 cycles of pre-denaturation at 
95 °C for 20 s, degeneration at 95 °C for 10 s, annealing at 
60 °C for 20 s, and extension at 70 °C for 20 s. This proce-
dure was repeated three times for each sample with a total 
reaction volume of 20  μL. The relative expression was 
calculated using 2−ΔΔCt (∆∆Ct =  ∆Ct (test specimen)—
∆Ct (authentic specimen), ∆Ct (test specimen) = Ct (test 
specimen, target gene)—Ct (test specimen, reference 
gene), ∆Ct (authentic specimen) =  Ct (authentic speci-
men, target gene)—Ct (authentic specimen, reference 
gene), 2−∆∆Ct = 2−(1.2) = 2.30).
Follow‑up
Discharged patients were followed up to further under-
stand their condition change and recovery situation. 
During their return visit, their symptoms of claudica-
tion and arterial pulse were examined. Postoperative 
CAT scanning was conducted, and the ankle-brachial 
index (ABI) was measured. Criteria for effective treat-
ment include the following: (1) stenosis in angiography 
vessel lumen less than 30%; (2) no obvious artery dissec-
tion or surgery-related complications; (3) resolution or 
improvement in claudication, rest pain, and other symp-
toms in the lower extremities as well as ulcer healing. If 
these criteria were not met, the treatment was regarded 
as invalid. Based on their recovery level, patients were 
assigned into the ISR group (n  =  74, 52 males and 22 
females, mean age: 65.4  ±  8.6  years) and the non-ISR 
group (n  =  91, 60 males and 31 females, mean age: 
64.7 ± 8.0 years).
Statistical analysis
SPSS21.0 statistical software was used for data analysis. 
Measurement data were presented as mean ± standard 
deviation (SD). The t test was used for the comparison 
between the two groups. Count data were expressed 
as a percentage or rate. Comparisons between the 
two groups were analyzed using the Chi-square test. 
Logistic regression analysis was performed to ana-
lyze the risk factors for postoperative ISR of LEAOD 
patients. A receiver operating characteristic (ROC) 
curve was drawn using statistical software to evaluate 
the diagnostic value of miRNA-143 in predicting ISR in 
LEAOD patients. P  <  0.05 was considered statistically 
significant.
Results
Comparison of clinical features of LEAOD patients 
between the restenosis and non‑restenosis groups
A total 165 patients who had undergone interventional 
treatment of LEAOD were followed up and assigned 
into the restenosis group (n = 74) or the non-restenosis 
group (n  =  91). The baseline characteristics of the two 
groups are compared in Table  2. There were significant 
differences in multiple indices before treatment, includ-
ing history of diabetes, smoking status, blood sugar level 
(BSL) at admission, low-density lipoprotein cholesterol 
(LDL-C) level, stent diameter, etc. (all P  <  0.05). How-
ever, there were no significant differences in age, gender, 
hypertension, or hyperlipidemia between the two groups 
(all P > 0.05).
Table 1 Primer sequence of  quantitative real-time poly-
merase chain reaction (qRT-PCR)
Primer Sequence (5′–3′) Length (bp)





miR‑143 Forward: TGTAGTTTTCGGAGTTAGTGTCGCGC 556
Reverse: CCTACGATCGAAAACGACGCGAACG
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Comparison of serum miRNA‑143 expression between the 
restenosis and non‑restenosis groups
There were significant differences in serum miRNA-143 
expression between the two groups. Compared with the 
non-restenosis group, serum miRNA-143 expression in 
the restenosis group was decreased (P < 0.05) (Fig. 1).
Correlation of serum miRNA‑143 expression 
with clinicopathological features between the restenosis 
and non‑restenosis groups
As presented in Table 3, the serum miRNA-143 expres-
sion in the restenosis group was correlated with smoking 
status, history of diabetes, BSL, and LDL-C (all P < 0.05), 
but it had no correlation with age or hyperlipidemia (both 
P  >  0.05). In the non-restenosis group, serum miRNA-
143 expression had no correlation with age, smoking sta-
tus, history of diabetes, BSL, LDL-C, or hyperlipidemia 
(all P > 0.05).
Logistic regression analysis of risk factors for postoperative 
ISR in LEAOD patients
As shown in Table  4, serum miRNA-143 expression, 
LDL-C, and smoking status were correlated with postop-
erative ISR (all P < 0.05). Both smoking status and LDL-C 
level were risk factors for ISR in LEAOD patients.
ROC curve analysis for the diagnostic value of miRNA‑143 
in predicting ISR in LEAOD patients
The area under the curve (AUC) was 0.866, which sug-
gested that miRNA-143 is a promising tool for predicting 
ISR in LEAOD patients (Fig. 2). Furthermore, the sensi-
tivity and specificity of miRNA-143 in predicting ISR in 
LEAOD patients were 83.7 and 82.6%, respectively.
Discussion
In recent years, endovascular interventional treatment 
has been an important treatment for the occlusive or 
stenosis diseases, especially LEAOD, of atherosclerosis 
[15], but postoperative restenosis remains as a big chal-
lenge for the treatment [1]. Although some studies have 
attempted to prevent ISR, we still do not have an optimal 
treatment [16]. Thus, finding an independent predictor of 
restenosis is of great significance for early management 
and prevention of ISR.
This study found that serum miRNA-143 expression 
in the restenosis group was significantly decreased when 
Table 2 Comparison of clinical features of patients in the restenosis and non-restenosis groups
BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol
Feature Restenosis group (n = 74) Non‑restenosis group (n = 91) P
Age (years) 65.4 ± 8.6 64.7 ± 8.0 0.583
Male, n (%) 52 (70.2) 60 (65.9) 0.553
BMI (kg/m2) 24.8 ± 3.6 24.1 ± 3.2 0.184
Hypertension, n (%) 19 (25.7) 22 (24.2) 0.825
Hyperlipidemia, n (%) 15 (20.3) 17 (18.7) 0.797
Renal dysfunction, n (%) 10 (13.5) 11 (12.1) 0.785
Diabetes, n (%) 21 (28.4) 6 (6.6) <0.001
Smoking, n (%) 59 (79.7) 27 (29.7) <0.001
Drinking, n (%) 33 (44.6) 40 (44.0) 0.935
SBP (mmHg) 137.8 ± 22.3 133.6 ± 21.5 0.221
DBP (mmHg) 73.4 ± 9.8 72.6 ± 7.7 0.558
HDL‑C (mmol/L) 1.1 ± 0.3 1.2 ± 0.3 0.177
LDL‑C (mmol/L) 3.0 ± 0.5 2.5 ± 0.3 <0.001
Blood sugar, (mmol/L) 6.3 ± 2.0 5.4 ± 1.8 <0.001

























Fig. 1 Comparison of microRNA‑143 expression between the reste‑
nosis and non‑restenosis groups. *Compared with the non‑restenosis 
group, P < 0.05
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compared with the non-restenosis group. The logis-
tic regression analysis also demonstrated that serum 
miRNA-143 expression was inversely related to the post-
operative ISR rate in LEAOD patients. The major patho-
genesis of posttreatment restenosis was the migration 
and proliferation of VSMCs. VSMCs can be stimulated 
by endothelial injury so that the medial and adventitial 
layers migrate to the intimal layer. Then, the neointima 
is generated and can lead to restenosis [17]. MiRNAs are 
known as vital regulators of many cellular events, and as a 
member of the miRNA family, miRNA-143 was reported 
to play a role in modulating VSMC phenotypes [18]. The 
serum response factor (SRF) is a transcription factor that 
plays a vital role in the regulation of VSMCs. It plays the 
role of a common docking site for both myogenic coacti-
vators and myogenic corepressors in VSMC phenotypic 
switching. Thus, as the transcription factor of miRNA-
143, Ets-like transcription factor-1 (ElK-1) combines with 
the SRF to repress VSMC growth [12]. In addition, angi-
otensin-converting enzyme (ACE-1) is one of the targets 
of miRNA-143. Also, ACE inhibitors have the potential 
to reverse vascular dysfunction [19]. It was found that 
serum miRNA-143 expression was decreased in states 
of atherosclerosis [20]. It was also discovered that serum 
miRNA-143 expression was decreased in the medial and 
intimal layers of the coronary artery during the develop-
ment of restenosis [21]. Patients in the ISR group had a 
significantly lower serum miRNA-143 expression than in 
Table 3 The relationships between microRNA-143 expression and clinical features of patients in the restenosis and non-
restenosis groups
LDL-C low-density lipoprotein cholesterol
Feature Restenosis group (n = 74) Non‑restenosis group (n = 91)
N Relative expression t P N Relative expression t P
Age (years)
 <60 40 0.53 ± 0.07 1.39 0.169 49 0.64 ± 0.14 0.64 0.526
 ≥60 34 0.51 ± 0.05 42 0.62 ± 0.16
Smoking
 Yes 59 0.50 ± 0.04 7.75 <0.001 27 0.62 ± 0.14 0.28 0.779
 No 15 0.60 ± 0.06 64 0.63 ± 0.16
Diabetes
 Yes 21 0.48 ± 0.04 3.51 0.001 6 0.62 ± 0.20 0.16 0.878
 No 53 0.53 ± 0.06 85 0.63 ± 0.15
Blood sugar
 High 14 0.45 ± 0.04 6.27 <0.001 19 0.60 ± 0.12 1.11 0.313
 Low 60 0.54 ± 0.05 72 0.64 ± 0.16
LDL‑C
 >2.6 mmol/L 35 0.49 ± 0.06 5.11 <0.001 20 0.61 ± 0.12 0.78 0.439
 ≤2.6 mmol/L 39 0.55 ± 0.04 71 0.64 ± 0.1
Hyperlipidemia
 Yes 15 0.51 ± 0.04 0.61 0.544 17 0.64 ± 0.15 0.74 0.459
 No 59 0.52 ± 0.06 74 0.63 ± 015
Table 4 Logistic regression analysis of risk factors for postoperative restenosis in patients with lower extremity arterial 
occlusive disease
miR-143 microRNA-143; LDL-C low-density lipoprotein cholesterol
Factor OR 95% CI P Partial regression  
coefficient
χ2 Standard error
miR‑143 0.001 0.000–0.077 0.001 −6.515 10.475 2.013
Blood sugar 0.905 0.708–1.157 0.427 −0.1 0.63 0.125
LDL‑C 9.953 2.629–37.678 0.001 2.298 11.446 0.679
Diabetes 1.31 0.368–4.670 0.677 0.27 0.174 0.648
Smoking 5.12 2.069–12.673 <0.001 1.633 12.476 0.462
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the non-restenosis group. Also, miRNA-143 was found 
to have a higher sensitivity and specificity for ISR diag-
nosis. Thus, miRNA-143 can be regarded as a biomarker 
for ISR [22]. This study also found that serum miRNA-
143 expression was decreased in the restenosis group 
compared with the non-restenosis group, suggesting 
that miRNA-143 has a good predictive ability for post-
operative restenosis. Therefore, it can be concluded that 
miRNA-143 can be involved in ISR development by regu-
lating VSMCs, and its expression can be used to predict 
postoperative restenosis.
In the logistic regression analysis of relevant factors 
of restenosis, it was found that LDL-C and smoking sta-
tus were the risk factors for restenosis. Because serum 
miRNA-143 expression levels are correlated with ISR 
occurrence, miRNA-143 potentially participates in the 
process of ISR development [22]. LDL-C is involved in 
the development of atherosclerosis and is an important 
risk factor for coronary artery disease (CAD). The regu-
lation of LDL-C can contribute to reductions in ISR 
rates [23]. In a previous study, smoking status was also 
predicted to be one of the risks factors of ISR develop-
ment [24]. Our study also demonstrates the relevance of 
miRNA-143, LDL-C, and smoking status to postopera-
tive restenosis by logistic regression analysis. Thus, these 
factors can be considered risk factors for restenosis.
In conclusion, RNA-143 expression plays an impor-
tant role in predicting restenosis in LEAOD patients, and 
can offer a theoretical basis for the treatment of LEAOD 
so that restenosis can be controlled by the regulation of 
miR-143 in VSMCs. However, more research needs to 
be done to explore the down-regulation mechanism of 
miNAR-143 in restenosis development to determine the 
most effective way to reduce the rate of restenosis by reg-
ulating miRNA-143.
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